Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387517 · ClinicalTrials.gov registry record · Phase 3
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 726
- Enrollment target
NCT00387517 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 726 participants.
The verdict
NCT00387517, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 726 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
Interventions
- DRUG Aliskiren/HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 726 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387517
The ClinicalTrials.gov registry entry for NCT00387517 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 726 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aliskiren/HCTZ is the first listed.
NCT00387517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387517 about?
NCT00387517 is a clinical study titled "Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension". The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
What is the current status of trial NCT00387517?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 726 participants. The study started on 2006-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00387517?
The interventions under investigation include: Aliskiren/HCTZ (DRUG).
Who is sponsoring clinical trial NCT00387517?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.